

Special Issue

Gene Therapy Coming of Age

Message from the Guest Editor

Gene therapy was once considered as the medicine of the future, back in the late 1990s, but it then suffered some unexpected setbacks in terms of virus-based delivery approaches. Nevertheless, gene therapy is now experiencing a second coming due to its improved efficacy and safety of vector delivery. This has led to the initiation of a large number of clinical trials and even approval of the first gene therapy drugs. Furthermore, recent progress in RNA interference, RNA delivery, and gene-editing technologies has broadened the application range of gene therapy. Today, both viral and nonviral vectors have found various applications for treatment of several diseases, such as cancer, metabolic, neurodegenerative, cardiovascular, and muscular diseases. The Special Issue on Gene Therapy in *Biomedicines* is therefore a particularly topical addition to the field, providing up-to-date insight into delivery vector types, safety-related issues, proof-of-principle in preclinical disease models, clinical trials in healthy volunteers and patients, and approval of gene therapy-based drugs.

Guest Editor

Dr. Kenneth Lundstrom

PanTherapeutics, Rue des Remparts 4, CH1095 Lutry, Switzerland

Deadline for manuscript submissions

closed (31 March 2021)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/29384

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).